Islet cell transplantation offers a potential cure for type 1 diabetes, but it is challenged by insufficient donor tissue and side effects of current immunosuppressive drugs. Therefore, alternative sources of insulin-producing cells and isletfriendly immunosuppression are required to increase the efficiency and safety of this procedure. Beta cells can be transdifferentiated from precursors or another heterologous (non-beta-cell) source. Recent advances in beta cell regeneration from somatic cells such as fibroblasts could circumvent the usage of immunosuppressive drugs. Therefore, generation of patient-specific beta cells provides the potential of an evolutionary treatment for patients with diabetes. Copyright © 2012 Xiaojie Wang et al.
CITATION STYLE
Wang, X., Metzger, D. L., Meloche, M., Hao, J., Ao, Z., & Warnock, G. L. (2012). Generation of transplantable beta cells for patient-specific cell therapy. International Journal of Endocrinology. https://doi.org/10.1155/2012/414812
Mendeley helps you to discover research relevant for your work.